blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1699760

EP1699760 - ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.03.2018
Database last updated on 30.03.2026
FormerThe patent has been granted
Status updated on  14.04.2017
FormerGrant of patent is intended
Status updated on  05.12.2016
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip29.05.2020Lapse of the patent in a contracting state
New state(s): PT		published on 01.07.2020  [2020/27]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2017/20]
Former [2012/33]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway NJ 07065-0907 / US
Former [2012/32]For all designated states
Schering Corporation
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Former [2010/10]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Former [2006/37]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Inventor(s)01 / GOULET, Mark, T.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
02 / UJJAINWALLA, Feroze
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
03 / VON LANGEN, Derek
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
 [2006/37]
Representative(s)Hussain, Deeba, et al
Merck Sharp & Dohme (UK) Limited
120 Moorgate
London EC2M 6UR / GB
[N/P]
Former [2017/20]Hussain, Deeba, et al
Merck Sharp & Dohme Limited
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU / GB
Former [2006/48]Buchan, Gavin MacNicol, et al
Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
Former [2006/37]Buchan, Gavin MacNicol, et al
Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road
Harlow, Essex CM20 2QR / GB
Application number, filing date04814836.517.12.2004
[2006/37]
WO2004US42698
Priority number, dateUS20030532096P23.12.2003         Original published format: US 532096 P
[2006/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005062824
Date:14.07.2005
Language:EN
[2005/28]
Type: A2 Application without search report 
No.:EP1699760
Date:13.09.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 14.07.2005 takes the place of the publication of the European patent application.
[2006/37]
Type: B1 Patent specification 
No.:EP1699760
Date:17.05.2017
Language:EN
[2017/20]
Search report(s)International search report - published on:US08.06.2006
(Supplementary) European search report - dispatched on:EP21.07.2010
ClassificationIPC:C07D205/08, A61P9/10, A61P3/06, A61K31/7052, A61K31/397, C07H15/26
[2006/37]
CPC:
C07D205/08 (EP,US); A61P3/06 (EP); A61P9/10 (EP);
C07H15/26 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/20]
Former [2006/37]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesLV24.07.2006
TitleGerman:ANTIHYPERCHOLESTERINÄMISCHE VERBINDUNGEN[2006/37]
English:ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS[2006/37]
French:COMPOSES ANTI-HYPERCHOLESTEROLEMIE[2006/37]
Entry into regional phase24.07.2006National basic fee paid 
24.07.2006Search fee paid 
24.07.2006Designation fee(s) paid 
24.07.2006Examination fee paid 
Examination procedure13.07.2006Amendment by applicant (claims and/or description)
24.07.2006Examination requested  [2006/37]
05.09.2011Despatch of a communication from the examining division (Time limit: M06)
13.03.2012Reply to a communication from the examining division
28.01.2015Despatch of a communication from the examining division (Time limit: M06)
28.07.2015Reply to a communication from the examining division
19.11.2015Despatch of a communication from the examining division (Time limit: M04)
18.03.2016Reply to a communication from the examining division
29.06.2016Despatch of a communication from the examining division (Time limit: M04)
03.11.2016Reply to a communication from the examining division
06.12.2016Communication of intention to grant the patent
06.04.2017Fee for grant paid
06.04.2017Fee for publishing/printing paid
06.04.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.09.2011
Opposition(s)20.02.2018No opposition filed within time limit [2018/17]
Fees paidRenewal fee
05.12.2006Renewal fee patent year 03
05.12.2007Renewal fee patent year 04
15.12.2008Renewal fee patent year 05
07.12.2009Renewal fee patent year 06
22.11.2010Renewal fee patent year 07
06.12.2011Renewal fee patent year 08
07.12.2012Renewal fee patent year 09
06.12.2013Renewal fee patent year 10
05.12.2014Renewal fee patent year 11
07.12.2015Renewal fee patent year 12
07.12.2016Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.12.2004
AT17.05.2017
CY17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
MC17.05.2017
NL17.05.2017
PL17.05.2017
PT17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
TR17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
[2020/27]
Former [2020/15]HU17.12.2004
AT17.05.2017
CY17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
MC17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
TR17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/46]HU17.12.2004
AT17.05.2017
CY17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
MC17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/31]HU17.12.2004
AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
MC17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/30]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
MC17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2018/51]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2018/50]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
BE31.12.2017
Former [2018/45]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
IE17.12.2017
LU17.12.2017
Former [2018/43]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
LU17.12.2017
Former [2018/25]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SI17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2018/11]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
IT17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2018/10]AT17.05.2017
CZ17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
RO17.05.2017
SE17.05.2017
SK17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2018/09]AT17.05.2017
DK17.05.2017
EE17.05.2017
ES17.05.2017
FI17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
SE17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2017/52]AT17.05.2017
ES17.05.2017
FI17.05.2017
LT17.05.2017
NL17.05.2017
PL17.05.2017
SE17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2017/50]AT17.05.2017
ES17.05.2017
FI17.05.2017
LT17.05.2017
PL17.05.2017
SE17.05.2017
BG17.08.2017
GR18.08.2017
IS17.09.2017
Former [2017/49]AT17.05.2017
ES17.05.2017
FI17.05.2017
LT17.05.2017
GR18.08.2017
IS17.09.2017
Documents cited:Search[YD] US5756470  (YUMIBE NATHAN P et al.) [YD] 1-14 * abstract * * column 2, line 35 * * column 3, line 52 * * column 4, line 52 *
 [Y] WO9417038  (SCHERING CORP et al.) [Y] 1-14 * abstract * * page 5, line 15 * * page 4, line 15 * * page 4, line 29 *
 [Y]   BURNETT D A ET AL: "Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/S0960-894X(01)00752-1, vol. 12, 1 January 2002 (2002-01-01), pages 315 - 318, XP002275927, ISSN: 0960-894X [Y] 1-14 * page 317, column 1, paragraph last * * page 317, column 1; table 1 *

DOI:   http://dx.doi.org/10.1016/S0960-894X(01)00752-1
International search[Y]   BURNETT D.A. ET AL: "Synthesis of fluorescent biochemical tools related tot the 2-azetidinone class of cholesterol absorption inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 3, 11 February 2002 (2002-02-11), pages 315 - 318, XP002275927

DOI:   http://dx.doi.org/10.1016/S0960-894X(01)00752-1
by applicant  GREENE, T; WUTS, P. G. M.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
   JAMA, vol. 285, 2001, pages 2486 - 2497
   DRUGS OF THE FUTURE, vol. 24, no. 5, 1999, pages 511 - 513
   BURNETT, D. S.; CAPLEN, M. A.; DOMALSKI, M. S.; BROWNE, M. E.; DAVIS, H. R. JR.; CLADER, J. W., BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 311
   DEAN, D.C. ET AL., J. MED. CHEM., vol. 39, 1996, pages 1767
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.